Utilization of radiotherapy and stereotactic body radiation therapy for renal cell cancer in the USA

References

• 1 National Comprehensive Cancer Network. Kidney Cancer. Version 2.2017. www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.
  Google Scholar
• 2 Deschavanne PJ, Fertil B. A review of human cell radiosensitivity in vitro. Int. J. Radiat. Oncol. Biol. Phys. 34(1), 251–266 (1996).
  Medline CASGoogle Scholar
• 3 Kjaer M, Iversen P, Hvidt V et al. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand. J. Urol. Nephrol. 21(4), 285–289 (1987).
  Medline CASGoogle Scholar
• 4 Timmerman RD, Hu C, Michalski J et al. Long-term results of RTOG 0236: a Phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage I non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 90(1), S30 (2014).
  Google Scholar
• 5 Verma V, Shostrom VK, Kumar SS et al. Multi-institutional experience of stereotactic body radiotherapy for large (≥5 centimeters) non-small cell lung tumors. Cancer 123(4), 688–696 (2017).
  MedlineGoogle Scholar
• 6 Verma V, McMillan MT, Grover S, Simone CB 2nd. Stereotactic body radiation therapy and the influence of chemotherapy on overall survival for large (≥5 centimeter) non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 97(1), 146–154 (2017).
  MedlineGoogle Scholar
• 7 Verma V, Shostrom VK, Zhen W et al. Influence of fractionation scheme and tumor location on toxicities following stereotactic body radiotherapy for large (≥5 centimeter) non-small cell lung cancer: a multi-institutional analysis. Int. J. Radiat. Oncol. Biol. Phys. 97(4), 778–785 (2017).
  MedlineGoogle Scholar
• 8 Verma V, Simone CB 2nd, Zhen W. Stereotactic radiotherapy for stage I small cell lung cancer. Oncologist 21(2), 131–133 (2016).
  MedlineGoogle Scholar
• 9 Verma V, Simone CB 2nd, Allen PK et al. Multi-institutional experience of stereotactic ablative radiation therapy for stage I small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 97(2), 363–371 (2017).
  Google Scholar
• 10 Verma V, Simone CB 2nd, Allen PK, Lin SH. Outcomes of stereotactic body radiotherapy for T1–T2N0 small cell carcinoma according to addition of chemotherapy and prophylactic cranial irradiation: a multicenter analysis. Clin. Lung Cancer 18(6), 675–681 (2017).
  MedlineGoogle Scholar
• 11 Teh B, Bloch C, Calli-Guevara M et al. The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT). Biomed. Imaging Interv. J. 3(1), e6 (2007).
  MedlineGoogle Scholar
• 12 Ippolito E, D'Angelillo RM, Fiore M et al. SBRT: a viable option for treating adrenal gland metastases. Rep. Pract. Oncol. Radiother. 20(6), 484–490 (2015).
  MedlineGoogle Scholar
• 13 Haque W, Butler EB, Teh BS. Stereotactic body radiation therapy for prostate cancer – a review. Chin. Clin. Oncol. 6(Suppl. 2), S10 (2017).
  MedlineGoogle Scholar
• 14 Verma V, Lazenby AJ, Zheng D et al. Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: secondary analysis of a prospective clinical trial. Radiother. Oncol. 122(3), 464–469 (2017).
  MedlineGoogle Scholar
• 15 Doh LS, Amato R, Paulino AC, Teh BS. Radiation therapy in the management of brain metastases from renal cell carcinoma. Oncology (Williston Park) 20(6), 603–613 (2006).
  MedlineGoogle Scholar
• 16 Teh BS, Bloch C, Paulino AC et al. Pathologic complete response in renal cell carcinoma brain metastases treated with stereotactic radiosurgery. Clin. Genitourin. Cancer 5(5), 334–337 (2007).
  MedlineGoogle Scholar
• 17 Svedman C, Karlsson K, Rutkowska E et al. Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol. 47(8), 1578–1583 (2008).
  Medline CASGoogle Scholar
• 18 Blanco AI, Teh BS, Amato RJ. Role of radiation therapy in the management of renal cell cancer. Cancers (Basel) 3(4), 4010–4023 (2011).
  MedlineGoogle Scholar
• 19 Jhaveri PM, Teh BS, Paulino AC et al. A dose-response relationship for time to bone pain resolution after stereotactic body radiotherapy (SBRT) for renal cell carcinoma (RCC) bony metastases. Acta Oncol. 51(5), 584–588 (2012).
  MedlineGoogle Scholar
• 20 Kothari G, Foroudi F, Gill S et al. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review. Acta Oncol. 54(2), 148–157 (2015).
  Medline CASGoogle Scholar
• 21 Siva S, Pham D, Gill S, Corcoran NM, Foroudi F. A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU Int. 110(11 Pt B), e737–e743 (2012).
  MedlineGoogle Scholar
• 22 Ranck MC, Golden DW, Corbin KS et al. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am. J. Clin. Oncol. 36(6), 589–595 (2013).
  Medline CASGoogle Scholar
• 23 Chang JH, Cheung P, Erler D et al. Stereotactic ablative body radiotherapy for primary renal cell carcinoma in non-surgical candidates: initial clinical experience. Clin. Oncol. (R. Coll. Radiol.) 28(9), e109–e114 (2016).
  Medline CASGoogle Scholar
• 24 Correa RJ, Rodrigues GB, Chen H et al. Stereotactic ablative radiotherapy (SABR) for large renal tumors: a retrospective case series evaluating clinical outcomes, toxicity, and technical considerations. Am. J. Clin. Oncol. doi:10.1097/COC.0000000000000329 (2016) (Epub ahead of print).
  MedlineGoogle Scholar
• 25 Verma V, Simone CB 2nd. Stereotactic body radiation therapy for metastases to the kidney in patients with non-small cell lung cancer: a new treatment paradigm for durable palliation. Ann. Palliat. Med. 6(2), 96–103 (2017).
  MedlineGoogle Scholar
• 26 Ponsky L, Lo SS, Zhang Y et al. Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma. Radiother. Oncol. 117(1), 183–187 (2015).
  MedlineGoogle Scholar
• 27 Ishiyama H, Blanco AI, Lo SS et al. Stereotactic body radiotherapy (SBRT)/stereotactic ablative body radiotherapy (SABR) for “radioresistant” renal cell carcinoma (RCC). J. Radiat. Oncol. 3(4), 339–346 (2014).
  Google Scholar
• 28 Siva S, Pham D, Kron T et al. Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial. BJU Int. 120(5), 623–630 (2017).
  MedlineGoogle Scholar
• 29 Kunkle DA, Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer 113(10), 2671–2680 (2008).
  MedlineGoogle Scholar
• 30 Bilimoria K, Stewart A, Winchester D, Ko C. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann. Surg. Oncol. 15(3), 683–690 (2008).
  MedlineGoogle Scholar
• 31 Siva S, Ellis RJ, Ponsky L et al. Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. Future Oncol. 12(5), 637–645 (2016).
  CASGoogle Scholar
• 32 Brower JV, Chen S, Bassetti MF et al. Radiation dose escalation in esophageal cancer revisited: a contemporary analysis of the National Cancer Data Base, 2004 to 2012. Int. J. Radiat. Oncol. Biol. Phys. 96(5), 985–993 (2016).
  MedlineGoogle Scholar
• 33 Qian G, Lowry J, Silverman P et al. Stereotactic extra-cranial radiosurgery for renal cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 57(2), S283 (2003).
  Google Scholar
• 34 Beitler JJ, Makara D, Silverman P, Lederman G. Definitive, high-dose-per fraction, conformal, stereotactic external radiation for renal cell carcinoma. Am. J. Clin. Oncol. 27(6), 646–648 (2004).
  MedlineGoogle Scholar
• 35 Wersäll PJ, Blomgren H, Lax I et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother. Oncol. 77(1), 88–95 (2005).
  MedlineGoogle Scholar
• 36 McGarry RC, Papiez L, Williams M et al. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: Phase I study. Int. J. Radiat. Oncol. Biol. Phys. 63(4), 1010–1015 (2005).
  MedlineGoogle Scholar
• 37 Alongi F, Arcangeli S, Triggiani L et al. Stereotactic ablative radiation therapy in renal cell carcinoma: from oligometastatic to localized disease. Crit. Rev. Oncol. Hematol. 117, 48–56 (2017).
  MedlineGoogle Scholar
• 38 Siva S, Jackson P, Kron T et al. Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: establishing a dose-response relationship. Radiother. Oncol. 118(3), 540–546 (2016).
  MedlineGoogle Scholar
• 39 Yamamoto T, Kadoya N, Takeda K et al. Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma. Radiat. Oncol. 11, 72 (2016).
  MedlineGoogle Scholar
• 40 Verma V, Bhirud AR, Denniston KA, Bennion NR, Lin C. Quantification of renal function following stereotactic body radiotherapy for pancreatic cancer: secondary dosimetric analysis of a prospective clinical trial. Radiat. Oncol. 12(1), 71 (2017).
  MedlineGoogle Scholar
• 41 Huang WC, Levey AS, Serio AM et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol. 7(9), 735–740 (2006).
  MedlineGoogle Scholar
• 42 Sun M, Bianchi M, Hansen J et al. Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis. Eur. Urol. 62(4), 696–703 (2012).
  MedlineGoogle Scholar
• 43 Campbell SC, Novick AC, Belldegrun A et al. Guideline for management of the clinical T1 renal mass. J. Urol. 182(4), 1271–1279 (2009).
  MedlineGoogle Scholar
• 44 Ljungberg B, Cowan NC, Hanbury DC et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur. Urol. 58(3), 398–406 (2010).
  MedlineGoogle Scholar
• 45 Plante K, Stewart TM, Wang D, Bratslavsky G, Formica M. Treatment trends, determinants, and survival of partial and radical nephrectomy for stage I renal cell carcinoma: results from the National Cancer Data Base, 2004–2013. Int. Urol. Nephrol. 49(8), 1375–1381 (2017).
  MedlineGoogle Scholar